Cardiovascular Endocrinology and Metabolism

Andrew Krentz has four decades of clinical and translational research experience in metabolic, endocrine and related cardiovascular disorders. His expertise in the life sciences includes preclinical and early-phase clinical drug development; he has personally contributed translational medical innovations to endocrinology clinical practice. He is actively involved in projects focused on precision diagnostics and therapeutics, digital healthcare, and healthy longevity that bridge the academic-industry spaces. Beyond his expertise in diabetes and endocrinology, he is accredited as a clinical specialist by the European Society for Hypertension and is a member of the Medical, Scientific & Research Committee of Heart UK. He is President-Elect of the Vascular, Lipid & Metabolism section of the Royal Society of Medicine as well as being a member of the European Group for the Study of Insulin Resistance (EGIR) and the Diabetes & Cardiovascular Study Group of the European Association for the Study of Diabetes (EASD). He has authored more than 200 scientific publications and founded the journal Cardiovascular Endocrinology & Metabolism and serves as Editor-in-Chief. Robert J. Chilton, DO, is a Clinical Professor of Medicine, Director of the Cardiac Catheterization Laboratory at University Hospital and the Audie L. Murphy VA Hospital, and Associate Program Director of the Interventional Cardiology Fellowship Program.A fellow of the American College of Cardiology, American College of Physicians, American College of Osteopathic Internists, and American Heart Association, Dr. Chilton also chairs the Electrophysiology Board Examination for the American Osteopathic Association and presides over the San Antonio chapters of both the Cardiovascular Society and American Heart Association.Over the past 20 years, Dr. Chilton has authored numerous articles, book chapters, abstracts, and presentations on cardiology. He has developed educational materials and has lectured widely, garnering several awards for his academic contributions, including 1994 Outstanding Teacher from the UT San Antonio.

*4 stars* "...an excellent resource for understanding the relationship between diagnosing and treating metabolic/endocrine disorders from an evidence-based cardiovascular standpoint,… [a] compact overview of what may soon become its own field of practice. …The authors are experts in the fields of endocrinology and cardiology and the contributors include nephrology and gastroenterology perspectives as well…. Many chapters, such as those on SGLT2 inhibitors and GLP receptor agonists, include summary tables of cardiovascular data from the major associated clinical trials…. [C]ontains chapters on nonalcoholic fatty liver disease as well as hemostatic diseases as they pertain to cardiovascular endocrinology and metabolism. [A] more high-level, clinical, and evidence- based [book], with many more contributors from various academic centers." --©Doody’s Review Service, 2023, Jessica Hwang, MD (Cook County Health)

• Part 1. Basic science and pathophysiology1. Obesity and insulin resistance2. Diabetes and macrovascular disease: epidemiology and cardiovascular risk assessment3. Hypertension4. Lipid metabolism: role in atherogenesis5. Renal disease and cardiorenal interactions6. NAFLD/NASH and cardiovascular risk7. Heart failure8. Prothrombosis: association with cardiometabolic disease9. Inflammation, metabolism and cardiovascular disease10. Classic endocrine disorders: association with vascular diseasePart 2. Clinical evaluation, lifestyle measures and therapeutic options11. Non-pharmacological strategies in the prevention and management of cardiometabolic disease12. Obesity: pharmacological approaches to prevention and management13. Diabetes: evolution of multifactorial vascular risk reduction14. Diabetes CVOTS: design, interpretation and future directions15. Novel glucose-lowering drugs: a new era of cardioprotection and renoprotection16: Hypertension: pharmacological and surgical management17. PCSK-9 inhibitors and other novel lipid-modifying drugs18. Recent therapeutic developments in heart failure19. Antiplatelet agents20. Progress in anticoagulant therapy21. Invasive treatment of atherosclerotic cardiovascular disease: today and tomorrow22. Cardiometabolic medicine in practice: role of cardiologists vs endocrinologists and the need for a new clinical specialty